Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
39.395
Open
38.050
VWAP
38.46
Vol
250.81K
Mkt Cap
781.15M
Low
37.970
Amount
9.64M
EV/EBITDA(TTM)
--
Total Shares
17.11M
EV
453.16M
EV/OCF(TTM)
--
P/S(TTM)
92.97
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company. It is focused on translating insights from genetic epilepsies into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, is an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. Its product candidates include ulixacaltamide, PRAX-562, PRAX-628 and elsunersen.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q2
FY2025Q1
194.35K
-35.65%
--
--
198.80K
-44.31%
--
--
183.10K
-57.52%
--
--
Estimates Revision
The market is revising Upward the revenue expectations for Praxis Precision Medicines, Inc. (PRAX) for FY2025, with the revenue forecasts being adjusted by 34.46% over the past three months. During the same period, the stock price has changed by -54.48%.
Revenue Estimates for FY2025
Revise Upward
+34.46%
In Past 3 Month
Stock Price
Go Down
-54.48%
In Past 3 Month
9 Analyst Rating
157.86% Upside
Wall Street analysts forecast PRAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRAX is 98.89 USD with a low forecast of 26.00 USD and a high forecast of 270.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
1 Sell
Strong Buy
157.86% Upside
Current: 38.350
Low
26.00
Averages
98.89
High
270.00
157.86% Upside
Current: 38.350
Low
26.00
Averages
98.89
High
270.00
Needham
Ami Fadia
Strong Buy
Reiterates
$80
2025-05-05
Reason
Needham
Ami Fadia
Price Target
$80
2025-05-05
Reiterates
Strong Buy
Reason
Wedbush
Laura Chico
Sell
Maintains
$26 → $28
2025-05-05
Reason
Wedbush
Laura Chico
Price Target
$26 → $28
2025-05-05
Maintains
Sell
Reason
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Reiterates
$105
2025-05-01
Reason
HC Wainwright & Co.
Douglas Tsao
Price Target
$105
2025-05-01
Reiterates
Strong Buy
Reason
Needham
Ami Fadia
Strong Buy
Reiterates
$85
2025-04-08
Reason
Needham
Ami Fadia
Price Target
$85
2025-04-08
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Douglas Tsao
Strong Buy
Maintains
$120 → $105
2025-03-03
Reason
HC Wainwright & Co.
Douglas Tsao
Price Target
$120 → $105
2025-03-03
Maintains
Strong Buy
Reason
Needham
Ami Fadia
Strong Buy
Maintains
$150 → $85
2025-03-03
Reason
Needham
Ami Fadia
Price Target
$150 → $85
2025-03-03
Maintains
Strong Buy
Reason
Needham lowered the firm's price target on Praxis Precision to $85 from $150 and keeps a Buy rating on the shares. The firm is removing Ulixa sales from its model after the company disclosed last week that Independent Data Monitoring Committee recommended that its study be stopped for futility, due to the results being unlikely to meet the primary efficacy endpoint, the analyst tells investors in a research note. At this time, the firm is assuming that the probability of success for this program is "minimal" until there is more clarity on the final topline, Needham added.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Praxis Precision Medicines Inc (PRAX.O) is -3.03, compared to its 5-year average forward P/E of -4.85. For a more detailed relative valuation and DCF analysis to assess Praxis Precision Medicines Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-4.85
Current PE
-3.03
Overvalued PE
-0.09
Undervalued PE
-9.61
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-3.16
Current EV/EBITDA
-1.19
Overvalued EV/EBITDA
1.05
Undervalued EV/EBITDA
-7.37
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
234.91
Current PS
949.01
Overvalued PS
634.71
Undervalued PS
-164.89
Financials
Annual
Quarterly
FY2025Q1
YoY :
-100.00%
0.00
Total Revenue
FY2025Q1
YoY :
+78.41%
-74.73M
Operating Profit
FY2025Q1
YoY :
+75.20%
-69.30M
Net Income after Tax
FY2025Q1
YoY :
+15.85%
-3.29
EPS - Diluted
FY2025Q1
YoY :
+154.16%
-53.01M
Free Cash Flow
FY2025Q1
YoY :
-100.00%
N/A
Gross Profit Margin - %
FY2025Q1
YoY :
-55.34%
-2.02K
FCF Margin - %
FY2025Q1
YoY :
-100.00%
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
1.1M
USD
2
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
79.4K
Volume
2
6-9
Months
0.0
Volume
0
0-12
Months
1.3M
Volume
4
Bought
0-3
0
0.0
Volume
Months
3-6
4
1.3M
Volume
Months
6-9
0
0.0
Volume
Months
0-12
10
3.0M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
1.1M
USD
2
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
PRAX News & Events
Events Timeline
2025-05-05 (ET)
2025-05-05
08:17:27
Praxis Precision hosted investor event on clinical programs
2025-05-02 (ET)
2025-05-02
08:37:50
Praxis Precision sees cash runway into 2028
2025-05-02
08:37:18
Praxis Precision reports Q1 EPS ($3.29), consensus ($3.21)
Sign Up For More Events
Sign Up For More Events
News
4.0
05-07BenzingaPraxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside
4.0
05-07BenzingaThis Waste Connections Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
4.0
05-07BenzingaChardan Capital Initiates Coverage On Praxis Precision Medicine with Buy Rating, Announces Price Target of $80
Sign Up For More News
People Also Watch
FOA
Finance of America Companies Inc
21.400
USD
+2.74%
LEGT
Legato Merger Corp III
10.580
USD
-0.19%
HDSN
Hudson Technologies Inc
7.460
USD
-4.36%
IRBT
iRobot Corp
2.550
USD
-4.49%
WTI
W&T Offshore Inc
1.370
USD
+1.48%
ACRS
Aclaris Therapeutics Inc
1.260
USD
-3.82%
FLIC
First of Long Island Corp
12.340
USD
-0.40%
GTE
Gran Tierra Energy Inc
4.530
USD
+2.95%
NREF
Nexpoint Real Estate Finance Inc
14.350
USD
+0.07%
PAL
Proficient Auto Logistics Inc
7.175
USD
-7.06%
FAQ
What is Praxis Precision Medicines Inc (PRAX) stock price today?
The current price of PRAX is 38.35 USD — it has increased 0.76 % in the last trading day.
What is Praxis Precision Medicines Inc (PRAX)'s business?
What is the price predicton of PRAX Stock?
What is Praxis Precision Medicines Inc (PRAX)'s revenue for the last quarter?
What is Praxis Precision Medicines Inc (PRAX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Praxis Precision Medicines Inc (PRAX)'s fundamentals?
How many employees does Praxis Precision Medicines Inc (PRAX). have?